At hubXchange's European Antibody Therapeutics event, Debby Kruijsen will lead a round-table discussion entitled 'Implementing...
ImmunoPrecise Antibodies has announced has appointed president and CEO Jennifer L Bath as a member of its board of directors as part of its annual review of management.
Chairman of ImmunoPrecise James Kuo said: “Under Jennifer’s leadership, ImmunoPrecise has evolved into the first full-service discovery antibody contract research organisation (CRO) in North America and Europe.
“Over the last three months, Jennifer oversaw our immediately accretive acquisition of ModiQuest, the addition of our new facility that provides B-cell sorting capabilities and our focus on antibody discovery for therapeutic antibodies. We are extremely supportive of Jennifer’s vision to create a global single-source CRO from inception of the target to clinical trials.”
Also as part of the expansion of its senior leadership team to achieve global growth objectives, the company is pleased to announce the appointments of Charles Wheelock as global chief technology officer (CTO) and Kari Graber as the director of global client services and project management.
CTO Charles Wheelock brings a diverse background to ImmunoPrecice Antibodies. He has held leadership positions within the software development and services industries over the past 25 years encompassing global enterprise resource planning (ERP) deployments, cloud transformations and building strategic line of business applications.
Mr Wheelock’s experience includes 16 years at Microsoft in various roles, most recently as a senior global technical account manager, where he drove both strategic and technical initiatives for many large organisations. Mr Wheelock holds a Bachelor’s Degree from the University of Kansas along with several industry and project management certifications.
Director of Global Project Management Kari Graber has more than 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance and supply chain management programmes for various food manufacturers. She spent five years as sales and technical director for a pasteurisation/sterilisation technology and equipment supplier.
Prior to joining ImmunoPrecise, Graber served at Aldevron, where she held a client relations management role for their antibody services platform. Kari holds a Bachelor of Science in Food Science and Technology with a Minor in Microbiology from North Dakota State University.
Jennifer L Bath said: “The expansion of our senior leadership in the areas of information technology, client services and project management positions ImmunoPrecise Antibodies to further its growth as a single provider of integrated antibody discovery for therapeutic drug discovery.
“We believe these positions further equip ImmunoPrecise Antibodies to fully integrate each of our business units located in North America and Europe to provide a seamless value chain to our clients as ImmunoPrecise Antibodies expands globally.”
At the same time as the company restructures to align each of North American and European business units for global growth, ImmunoPrecise Antibodies wishes to acknowledge the contribution of Reg Beniac, former Chief Operating Officer (COO) who has moved on to other opportunities.
Mr Beniac stepped in as COO and steered the company through a transformational time. He played a central role in moving ImmunoPrecise Antibodies from a private to a public company model, was a key member of the acquisition team, returned the Victoria business to operational profitability, and led credibly during executive-level staffing changes.
Immunoprecise Antibodies has announced that it has opened a new subsidiary office in Cambridge, Massachusetts,...
ImmunoPrecise Antibodies has increased its non-brokered private placement financing to 875,000 units of ImmunoPrecise at...